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The role of the RAS pathway in iAMP21-ALL
SL Ryan1, E Matheson1, V Grossmann2, P Sinclair1, M Bashton3, C Schwab1, W Towers1, M Partington1, A Elliott1, L Minto1,
S Richardson1, T Rahman4, B Keavney4,5, R Skinner1, N Bown4, T Haferlach2, P Vandenberghe6, C Haferlach2, M Santibanez-Koref4,
AV Moorman1, A Kohlmann2,7, JAE Irving1 and CJ Harrison1
Intrachromosomal ampliﬁcation of chromosome 21 (iAMP21) identiﬁes a high-risk subtype of acute lymphoblastic leukaemia (ALL),
requiring intensive treatment to reduce their relapse risk. Improved understanding of the genomic landscape of iAMP21-ALL will
ascertain whether these patients may beneﬁt from targeted therapy. We performed whole-exome sequencing of eight iAMP21-ALL
samples. The mutation rate was dramatically disparate between cases (average 24.9, range 5–51) and a large number of novel
variants were identiﬁed, including frequent mutation of the RAS/MEK/ERK pathway. Targeted sequencing of a larger cohort
revealed that 60% (25/42) of diagnostic iAMP21-ALL samples harboured 42 distinct RAS pathway mutations. High sequencing
coverage demonstrated heterogeneity in the form of multiple RAS pathway mutations within the same sample and diverse variant
allele frequencies (VAFs) (2–52%), similar to other subtypes of ALL. Constitutive RAS pathway activation was observed in iAMP21
samples that harboured mutations in the predominant clone (⩾35% VAF). Viable iAMP21 cells from primary xenografts showed
reduced viability in response to the MEK1/2 inhibitor, selumetinib, in vitro. As clonal (⩾35% VAF) mutations were detected in 26%
(11/42) of iAMP21-ALL, this evidence of response to RAS pathway inhibitors may offer the possibility to introduce targeted therapy
to improve therapeutic efﬁcacy in these high-risk patients.
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INTRODUCTION
Acute lymphoblastic leukaemia (ALL) is the most common child-
hood cancer. Chromosomal abnormalities deﬁne subgroups of ALL,
often related to distinct clinical features and outcome.1 Recurrent
copy number abnormalities (CNAs) and somatic mutations have
been identiﬁed in genes within key cell-signalling pathways.2–5 The
involvement of different pathways is ALL subgroup speciﬁc, and
their clinical and biological signiﬁcance is related to the genomic
background on which they occur.3,6,7 A range of inhibitors are being
developed to target key signalling pathways, and experimental
studies have shown response to these inhibitors in primary ALL
cells.4,8,9 Thus, understanding the biological and clinical role of such
abnormalities in individual ALL subgroups may have future
therapeutic beneﬁt.10
Patients with intrachromosomal ampliﬁcation of chromosome 21
(iAMP21) comprise a distinct subgroup of childhood ALL at an
incidence of 2%. They are older (median age 9 years) with a low
white blood cell count (o50×109/L) and have a high risk of relapse
on standard therapy.11 Recently, we and others have shown that
intensive treatment signiﬁcantly improves outcome.12–15 The
abnormal chromosome 21 deﬁning iAMP21 is highly heterogeneous
with a complex array of rearrangements that affect copy number
and localisation of many genes on chromosome 21.16 Although the
mechanism behind the formation of this intriguing abnormality is
understood, the target gene(s) and contributing leukaemogenic
factor(s) remain unknown.
In this study, we explored the mutational landscape of iAMP21-
ALL using next-generation sequencing technologies and discovered
a high incidence of novel mutations, including frequent somatic
mutation of genes within the RAS signalling pathway. Furthermore,
we showed that MEK1/2 inhibition has a negative effect on viability
of iAMP21-positive cells with phosphorylated ERK (pERK) expression.
These ﬁndings suggest that RAS pathway deregulation is of
biological relevance in iAMP21-ALL, which may offer alternative
treatment approaches in these high-risk patients.
MATERIALS AND METHODS
Patient details
The study included diagnostic (n= 44), matched remission (n= 19) and/or
relapse (n= 7) bone marrow samples from ALL patients with iAMP21,
and 48 and 66 diagnostic samples from patients with high hyperdiploidy
(51–65 chromosomes) or no recurrent cytogenetic abnormality (B-other
ALL), respectively (Supplementary Table 1). Studies were approved by the
relevant institutional review boards, and written informed consent was
obtained for each patient. DNA and RNA were extracted from bone marrow
using the DNeasy and RNeasy Extraction kit (Qiagen, Manchester, UK),
respectively. Whole-genome ampliﬁcation of 20 ng DNA was performed
using the Repli-G kit (Qiagen). A schema of the experimental approach is
shown in Supplementary Figure 1.
Cytogenetic analysis
Cytogenetic analysis and ﬂuorescence in situ hybridisation were carried
out, as previously reported.17 Patients were diagnosed with iAMP21-ALL, as
described in Supplementary Table 1.
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SNP6.0 array analyses
SNP6.0 array analysis (Affymetrix, Santa Clara, CA, USA) was carried out on
iAMP21-ALL cases with sufﬁcient DNA: diagnostic (n= 28) with matched
relapse (n= 2) and remission (n= 17) (Supplementary Table 1). Arrays were
prepared and analysed as described in Supplementary Table 2.
Multiplex Ligation-dependent Probe Ampliﬁcation
The SALSA MLPA P335-IKZF1 kit (MRC Holland, Amsterdam, The Netherlands)
was used to assess the copy number of 8 signiﬁcant ALL-associated genes
in 38 diagnostic and 6 relapse samples, as previously described.18 Matched
SNP6.0 array data were available for 22 diagnostic and 1 relapse sample.
Whole-exome sequencing
Whole-exome sequencing (WES) was performed on matched diagnostic
and remission samples of eight iAMP21-ALL patients. Library preparation,
sequencing, data analysis and validation of putative mutations were
performed as described in Supplementary Text.
Targeted sequencing approaches
Speciﬁc RAS pathway genes (BRAF, NRAS, KRAS, FLT3, PTPN11 and NF1) were
sequenced in a cohort of diagnostic (n=42), relapse (n=7) and remission
(n=9) iAMP21-ALL, diagnostic B-other (n=66) and high hyperdiploid
(n=48) samples, using amplicon sequencing (Supplementary Table 1). Primer
sequences are detailed in Supplementary Table 3. Targeted sequencing was
performed in two screens (A and B), as described in Supplementary Figure 1.
Amplicon libraries were sequenced on the Roche 454 GS FLX or GS Junior
sequencer at the Munich Leukemia Laboratory (Munich, Germany) or
NewGene (Newcastle upon Tyne, UK) and on the Illumina MiSeq by Source
Bioscience (Nottingham, UK). Data analysis was performed using SeqNext
version 3.4.0 (JSI Medical Systems, Kippenheim, Germany), and mutations were
identiﬁed by manual assessment using criteria described in Supplementary
Figure 1.
Reverse transcription PCR
The iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA) was used to
synthesise cDNA from 100 ng RNA. Primers were designed to exons 13 and
16 of FLT3 (Supplementary Table 3). PCR was performed using peqGOLD
Taq DNA polymerase (Peqlab, Erlangen, Germany).
Western blotting
Protein was extracted from bone marrow samples and cell lines to assess
levels of pERK (catalogue #4370, New England BioLabs, Ipswich, MA, USA)
relative to ERK (sc-153, Santa Cruz Biotechnology, Dallas, TX, USA), as
previously described.5 Two iAMP21-ALL samples (patients 1 and 7) and six
positive/negative control samples (four patient samples and two cell lines,
REH and CCRF-CEM) were used in western blotting analysis. Cell lines were
obtained from European Collection of Cell Cultures or American Tissue
Culture Collection and were authenticated and tested for mycoplasma
contamination before use.
Cytotoxic assessment of MEK1/2 inhibitors
Primary leukaemia cells from four iAMP21-ALL (patients 1, 14, 45, and 46b)
were successfully transplanted into female NOD/LtSz-scid IL2Rγ null (NSG)
mice, as previously described.19 Animal experiments were carried out
in accordance with the UK Home Ofﬁce Animals (Scientiﬁc Procedures) Act
(ASPA) 1986 under project licence PPL60/4552. RAS gene mutations were
screened in the diagnostic (patients 1 and 14) and/or primagraft (patients
1, 14, 45 and 46b) material, based on DNA availability. Viable leukaemia
cells from the primagrafts were used to assess the cytotoxicity of the
MEK1/2 inhibitor, selumetinib, as detailed previously.8
RESULTS
WES and genomic analysis of iAMP21-ALL
WES identiﬁed 199 somatic mutations in 8 iAMP21-ALL samples that
were predicted to be deleterious to protein function (Supplementary
Table 4). All mutations selected for validation (n=106) were
conﬁrmed to be somatically acquired (Supplementary Text). The
number of mutations was variable in each patient sample, ranging
from 5 to 51 (average, 24.9), and on average the mutated allele was
represented in 33% (range 4–100%) of reads; this value was
designated the variant allele frequency (VAF). Most of the mutations
were novel (73%, 146/199) and not previously reported in cancer
(Catalogue of Somatic Mutations in Cancer, COSMIC). Substitutions,
insertions and/or deletions were identiﬁed, which generated
missense, in-frame, frameshift and splice site variations. Recurrent
mutations were identiﬁed in four genes; NRAS, CAPN5, FLT3LG and
DOCK11, in two samples each. Interestingly, nine mutations were
detected in components of the RAS pathway in 75% (6/8) of
iAMP21-ALL samples. Six mutations had been previously reported in
cancer, NRAS, p.G12S (n=2), FLT3LG pQ114fs (n= 2), FLT3 p.N676K
and PTPN11 p.A72T; three mutations were novel, RASGRP3 p.E445K,
NF1 p.P1667S and CBL p.E113Q. The average VAF of RAS pathway
mutations was 31% (range 6–67%). Four samples harboured
mutations that were representative of the major clone (⩾35% VAF).
The type of substitution (for example: transition, C4T) and
sequence context in which it arises can deﬁne a ‘mutational
signature’, which can be created by an endogenous or environ-
mental factor.20,21 In the iAMP21-ALL exome, transitions were more
common than transversions or indels, and 186 nucleotide substitu-
tions were observed, predominantly composed of C:G4T:A sub-
stitutions that were enriched at CpG or TpC sites (Supplementary
Figure 2).
RAS pathway abnormalities are common in iAMP21-ALL
Discovery of this high incidence of RAS pathway mutations
by WES, prompted us to investigate the true incidence of RAS
pathway mutations in iAMP21-ALL. From screening of 42
diagnostic and 5 relapse samples using targeted sequencing
approaches (Supplementary Figure 1), distinct mutations (n= 44)
were identiﬁed in 26 samples overall (Figure 1, Supplementary
Figure 3 and Supplementary Table 5), with a lower frequency at
relapse (20%, 1/5) than diagnosis (60%, 25/42). Most mutations
(89%, 39/44) had been previously reported in cancer (COSMIC)
and all variants were consistently predicted to alter protein
function. The mutational proﬁle differed between diagnosis and
relapse in seven matched samples (Supplementary Table 6).
Testing of matched remission material (n= 9) conﬁrmed the
somatic nature of the mutations in eight patients (Supplementary
Table 1); however, PTPN11 p.N58S was identiﬁed as a hetero-
zygous variant in both diagnostic and remission samples of
one patient (Figure 1e and Supplementary Figure 3). Germline
mutations of PTPN11 have been previously associated with
Noonan and Leopard Syndromes, with an increased risk of
developing cancer.5,22
RAS pathway abnormalities are genetically heterogeneous
The 44 mutations involved NRAS (45%, 20/44), KRAS (18%, 8/44),
FLT3 (20%, 9/44), PTPN11 (11%, 5/44), BRAF (2%, 1/44) and
NF1 (2%, 1/44) (Figure 1 and Supplementary Figure 3). The RAS
pathway mutations were shown to coexist within a gene or
individual patient sample in patterns which ranged from 2–3
mutated genes to 2–4 mutations affecting the same gene in one
sample. In eight cases, where one exon was affected by ⩾2
mutations, the variants were consistently observed in different read
populations, indicating individual alleles or subclones, of which the
latter would increase the overall mutational burden in these
samples (Supplementary Figure 4). In one exception (patient 5),
the germline variant, PTPN11 p.N58S, and somatic mutation, PTPN11
p.A72T, were identiﬁed within the same allele. The clonal origin of
the mutations in different genes/exons could not be determined
from the sequencing data in the remaining six cases, as they were
located within different amplicons.
Consistent with this mutational heterogeneity, VAF differed
between individual patient samples and RAS pathway genes
(range 2–52%) (Figure 1 and Supplementary Figure 3). Overall,
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26% (11/42) of diagnostic iAMP21-ALL cases harboured single or
multiple RAS pathway mutations that, when combined, repre-
sented the major clone (total VAF ⩾ 35%); subclonal mutations
were observed in 34% (14/42) of the cohort. PTPN11 was
frequently mutated at a higher frequency (average VAF, 35%)
than NRAS, KRAS, or FLT3, which were often mutated in ⩽ 18% of
reads. The single NF1 and BRAF mutations were detected at levels
representative of the dominant clone (⩾35%). Interestingly, FLT3
was most frequently exclusively mutated (78%, 7/9 cases),
whereas NRAS, KRAS and PTPN11 rarely represented isolated
mutations (⩽31% cases). The cohort was too small to determine
the signiﬁcance of these observations.
Detection of RAS pathway mutations in other ALL subgroups
To investigate the distinct genetic proﬁle of RAS pathway mutations
in iAMP21-ALL, the same screening approach was performed on
samples from high hyperdiploid (n= 48) and B-other ALL patients
(n= 66). RAS pathway gene mutations were frequent in these
subgroups, occurring in 85% (41/48) and 44% (29/66) of cases,
respectively (Figure 2 and Supplementary Figure 5). These subgroups
were selected for comparative analysis with iAMP21-ALL because
they are known to have a high incidence of RAS pathway mutations,
acquire extra copies of chromosome 21 (high hyperdiploidy) or have
a similar gene expression proﬁle (B-other).3,9,23,24
Comparable patterns of genetic heterogeneity and subclonal
KRAS, NRAS and FLT3 mutations were identiﬁed in both subgroups
(Figure 2 and Supplementary Figure 5). Signiﬁcant mutational
burden (VAF ⩾ 35%) was observed in 42% (20/48) and 8% (5/66) of
high hyperdiploid and B-other ALL, respectively, compared with
26% (11/42) of diagnostic iAMP21-ALL. FLT3 mutations were
frequently found at a lower VAF in all subgroups, but tended to
arise independently of other RAS pathway gene mutations only in
iAMP21-ALL. FLT3 mutation types ranged from substitutions to
indels and varied according to the ALL subgroup in which they
occurred; while substitutions and indels were common in high
hyperdiploid and B-other ALL, FLT3-ITD was signiﬁcantly more
prevalent in iAMP21-ALL (χ2 test, ITD versus non-ITD in iAMP21
and non-iAMP21-ALL, P= 0.0001).
CNAs affecting RAS pathway genes
To determine the relationship between CNA and RAS pathway
mutations in iAMP21-ALL, SNP6.0 array and MLPA (Multiplex
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Figure 1. The nature and incidence of RAS pathway mutations in iAMP21-ALL. (a–d) Protein domain and alteration plots for RAS pathway
genes that harbour mutations in 26 iAMP21-ALL samples: 44 mutations were identiﬁed in NRAS (a), FLT3 (B), KRAS (c) and PTPN11 (d). Each
coloured line depicts the type of mutation (mismatch (red), deletion (black), insertion (green) and frameshift (blue)), and the amino-acid
change is stated above the position/line. Most of the mutations had been previously reported in cancer (COSMIC), were frequently located in
hotspot mutation regions within the gene and often observed as internal tandem duplications (ITD) in FLT3. The coloured circles represent the
26 individual samples; those cases with a single RAS pathway mutation are coloured black and each sample with multiple mutations is
deﬁned by a distinct colour. (e) The co-occurring nature of RAS pathway mutations is shown in 26 iAMP21-ALL patient samples. Each sample is
labelled on the x axis and the y axis deﬁnes the VAF (%) of each mutation. The pattern/colour of each bar represents the mutated gene, as
depicted by the key. *PTPN11 p.N58S, present in the matched diagnosis and remission sample. The protein domain and alteration plots were
generated using The Protein Painter application in the Pediatric Cancer Genome Project (http://explore.pediatriccancergenomeproject.org).
The role of the RAS pathway in iAMP21-ALL
SL Ryan et al
3
© 2016 Macmillan Publishers Limited Leukemia (2016) 1 – 8
Ligation-dependent Probe Ampliﬁcation) data were available for
30 (28 diagnostic and two relapse) and 44 (38 diagnostic and six
relapse) samples, respectively, for which the mutational status of
the RAS pathway was known. There was 100% concordance
(42/42 abnormalities) between the MLPA and SNP6.0 array data in
samples (n= 22) assessed using both methods. RB1 and ETV6
deletions were frequent in 41% (20/49) and 33% (16/49) of cases,
respectively, as previously shown.18,25 CNA affecting components
of the RAS pathway was identiﬁed in 53% (16/30) of cases but
were not observed alongside gene mutations (Figure 3 and
Supplementary Table 2). The CNA often involved large (41 Mb)
regions (95%, 20/21) of chromosomes recurrently abnormal in
iAMP21-ALL, for example loss/deletion of chromosomes 7/7q
(BRAF locus) and 11q (CBL locus).14 One focal CNA (75 kb) targeted
only the FLT3 locus (patient 9), although the other allele was not
mutated. Regions of copy number neutral loss of heterozygosity
(CNN-LOH) were not observed for RAS pathway genes among
patients in this cohort. Although limited by small sample size, a
trend was observed for an association between RAS pathway
mutations and IKZF1 deletions (Fisher’s exact test, P= 0.065).
The biological signiﬁcance and utility of RAS pathway mutations
as therapeutic targets
To elucidate the biological signiﬁcance of RAS pathway mutations in
iAMP21-ALL, protein analysis was performed to assess pERK levels in
samples with sufﬁcient material. Constitutive RAS pathway activa-
tion was conﬁrmed in patient 1 (NF1 p.P1667S and NRAS p.Q22K),
although the pERK level was lower than the positive control samples
(CEM and L897), which both harboured KRAS p.G12D mutations
(Figure 4). Patient 7 (FLT3 p.P606_R607ins10, VAF=4%) showed no
detectable pERK, demonstrating that this FLT3 mutation did not
activate the RAS/RAF/ERK pathway, or at least not at detectable
levels (Supplementary Figure 6). RT-PCR (reverse transcription PCR),
performed on patient 7 and two additional iAMP21-ALL samples
(patients 11 and 21), conﬁrmed that the normal and mutant FLT3
alleles were transcriptionally expressed in cases harbouring FLT3-ITD
at 4–13% VAF (Figure 4e).
Therapeutic inhibitors of the RAS pathway are currently in clinical
trial and have previously been shown to induce apoptosis in ALL
cells with aberrant RAS pathway activation.5,8,26 To assess the
therapeutic beneﬁt of RAS/RAF/ERK pathway inhibitors in iAMP21-
ALL, viable cells from xenografts of diagnostic leukaemia cells from
RAS mutant patients 1 and 14 were tested. The same mutations
identiﬁed in the diagnostic sample were present in the 1°, 2° and 3°
xenograft material (Supplementary Figure 6). The 3° xenograft
material from two other iAMP21-ALL patients negative for RAS
pathway mutations was used as controls. Sensitivity to the MEK1/2
inhibitor, selumetinib (AZD6244), was observed in vitro in associa-
tion with inhibition of RAS pathway signalling, evidenced by
reduced pERK levels, in patients 1 and 14 only (Figure 4).
DISCUSSION
This is the ﬁrst study of the mutational landscape of iAMP21-ALL.
We have shown that the total number of mutations is variable
(5–51 somatic mutations per case); higher than the average
mutation rate in other ALL subtypes (iAMP21, 24.9; ETV6-RUNX1,
14; high hyperdiploidy, 7.5; hypodiploidy, 10.9; MLL-rearranged, infant
1.3, children 6.5).4,27–29 The mutational signature can indicate
the endogenous or environmental factor that is involved in the
development of a speciﬁc disease.20,21 The signature of iAMP21-ALL
appeared to be similar to other ALL series, exhibiting a high rate of
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Figure 2. Nature of RAS pathway mutations in other ALL subgroups. KRAS, NRAS and FLT3 were sequenced in patient samples with high
hyperdiploid (n= 48) or B-other ALL (n= 66). Only exonic regions that were mutated in the iAMP21-ALL cohort were assessed. (a) The
incidence of mutations in high hyperdiploid, iAMP21 and B-other ALL ranged from 44 to 85%; the proportion of cases with signiﬁcant
mutational burden (⩾35% VAF (black bar)) or subclonal mutation (o35% VAF (patterned bar)) is shown. (b) VAF of KRAS, NRAS and FLT3
mutations in high hyperdiploid, iAMP21 and B-other ALL is demonstrated. Subclonal mutations were identiﬁed for each gene, independent of
ALL subgroup. (c, d) Protein domain plots for FLT3 mutations in 17 high hyperdiploid (c) (20 mutations) and 5 B-other (d) (10 mutations)
patient samples. Each coloured line depicts the type of mutation (mismatch (red), deletion (black), insertion (green) and splice site mutation
(gold)), and the amino-acid change is stated above the position/line. The coloured circles represent individual samples; those cases with a
single RAS pathway mutation are coloured black and samples with multiple mutations are deﬁned by a white circle.
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C4T substitutions at CpG and TpC sites.21,28,30 This signature is
associated with DNA methylation; the most widespread mutational
process in genome evolution and cancer. Novel recurrent mutations
were identiﬁed in genes not previously associated with childhood ALL;
CAPN5, FLT3LG and DOCK11, suggesting that somemutations involved
in iAMP21-ALL may be unique to this subgroup.
Our initial novel discovery of RAS pathway mutations in 6/8
iAMP21-ALL patients by WES led to the ﬁnding of a high incidence
(60%) of these mutations in iAMP21-ALL at diagnosis. This high
incidence may reﬂect the sensitivity of the targeted sequencing assay
for the detection of subclonal mutations (Supplementary Figure 1).
However, recent studies using similar targeted sequencing
approaches have reported comparable incidences and patterns of
RAS mutations in other ALL subtypes.4,9,24,27,29 In this study, subclonal
and coexisting RAS mutations were observed, similar to these in
iAMP21-ALL, in high hyperdiploid and B-other ALL. Subclonal
mutations (o35% VAF) that coexisted were consistently identiﬁed
in distinct read populations, representing individual alleles or
subclones. Single-cell genomic studies have demonstrated that
subclonal KRAS and NRAS mutations are often present in distinct
clones in other cancer types, and frequent convergence from
multiple RAS mutated subclones at diagnosis to a single clonal RAS
mutation at relapse has been reported in ALL.24,31,32 Considering
these data, coexisting subclones of RAS mutations detected in this
study likely represent individual subclones, which collectively
increase the total mutational burden within a single sample. The
observation that most cases had detectable subclonal mutations
demonstrates their potentially important role in ALL development.
The coexistence of a range of low frequency variants may offer
multiple routes for leukaemia development. RAS pathway mutations
have been variously described as mutually exclusive or coexistent
within other cancer subtypes,33 indicating that coexisting mutations
may be required to achieve neoplasia in speciﬁc tissues or
environments. Furthermore, multiple subclones with different RAS
pathway mutations may provide a mechanism by which the
leukaemic cells evade the effects of treatment. Our previous studies
demonstrated that RAS pathway mutations can drive relapse and
generate a more chemo-resistant phenotype, supported by the
enrichment of KRAS mutant cells during induction chemotherapy
and the observation of RAS gene mutations consistently in the major
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Figure 3. The association between RAS pathway mutations and CNAs in iAMP21-ALL. iAMP21-ALL patient samples (n= 49, 42 diagnostic and 7
relapse) were screened for (a) RAS pathway mutations, (b) RAS pathway CNAs by SNP6.0 array analysis of 30 iAMP21-ALL cases (28 diagnostic
and 2 relapse samples) and (c) CNA that affects genes recurrently aberrant in ALL. *Two relapse cases were used to validate the diagnostic-
speciﬁc nature of RAS gene mutations, but they were not included in the mutation screening cohort. Grey denotes that the genomic assay
was not performed. The type and VAF (%) of the mutation and the copy number (CN) status of the gene are represented by the respective
colour. CRLF2 abnormalities are shown in purple. Only genes that harboured mutations or CNA are displayed. CNA was frequently observed in
genes (BRAF, NF1, CBL) located on chromosomes recurrently abnormal in iAMP21-ALL but they were not observed alongside mutations in
cases analysed by targeted or whole-exome sequencing.14 There was a trend towards co-occurrence of IKZF1 deletions and RAS mutations
(Fisher’s exact test, P = 0.065).
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clone at relapse.8 In this study, NRAS p.G12D and PTPN11 p.R351Q
were detected in one iAMP21-ALL relapse sample as heterozygous
variants (48% VAF). Although they were not detected in the matched
diagnostic sample, it is possible that they were present in a low level
subclone. The role of RAS mutant subclones in driving relapse is not
well understood, as demonstrated by lack of correlation in the
genomic proﬁle of seven matched diagnostic and relapse samples in
our study.
In iAMP21-ALL, somatic mutations frequently occurred in
hotspot regions of the RAS pathway, generating amino-acid
changes in key domains predicted to affect the function of the
protein. Accompanying loss of the normal allele, leading to
homozygosity of the mutant allele, has been reported in other
subtypes of ALL, including hypodiploidy.4 Although a high
incidence of CNA (53%) was observed in components of the
RAS pathway in iAMP21-ALL, they did not coexist with mutations,
implying that homozygosity or CNN-LOH of RAS pathway genes is
not important in this subtype. Most CNA involved large (41 Mb)
chromosomal regions that were recurrently abnormal in iAMP21-
ALL, which included multiple genes.14 However, mutation of
neighbouring genes within the regions of CNA was not observed
from WES, implicating that loss or gain of the functional gene,
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Figure 4. The biological signiﬁcance of RAS pathway mutations in iAMP21-ALL. (a) Western blot analysis was used to investigate the biological
effect of RAS pathway mutations in patient 1 (bold text), relative to positive (KRAS mutated) and negative (wild type (WT)) control samples
from our previous studies.5,8 pERK was observed in the positive control samples and patient 1, which harboured NF1 p.P1667S and NRAS
p.Q22K. Absent pERK was observed in the negative control samples. (b, c) Cytotoxicity assays were performed using the MEK1/2 inhibitor,
selumetinib, on viable cells from the xenografts of patients 1, 14 and the xenograft material of two iAMP21-ALL patients that did not harbour
RAS pathway mutations (patients 45 and 46b) (Supplementary Figure 6). (b) Reduced pERK levels conﬁrmed the inhibitory effect of
selumetinib on RAS pathway signalling exclusively in the mutated samples. pERK expression was not detected in the RAS normal xenograft
samples (data not shown). (c) Sensitivity to selumetinib was observed in the RAS mutant samples (patients 1 and 14) only. (d) Bar chart of GI50
values after dosing with selumetinib for the xenografts of patients 1, 14, 45 and 46b, compared with RAS mutant and non-mutated ALL
samples from our previous study.8 A similar level of sensitivity to selumetinib was observed in patients 1 and 14, compared with other RAS
mutant ALL samples. Similarly, the response observed in patients 45 and 46b was equivalent to non-mutated ALL samples. (e) Transcript
expression of FLT3-ITD and normal FLT3 allele in patients 7, 11 and 21, as measured by RT-PCR. FLT3-ITD was expressed in all mutant cases with
VAF of 13% (patient 21), 4% (patient 7) and 9% (patient 11). MUTZ5 was used as a control for normal FLT3 expression. A 100-bp DNA ladder
(Promega, Madison, WI, USA) was used to determine the PCR product size.
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rather than homozygosity of the mutant allele, is important in
iAMP21-ALL leukaemogenesis.
Most of the RAS pathway gene mutations reported here have
been previously described in other ALL or cancer types (http://
cancer.sanger.ac.uk/cancergenome/projects/cosmic/). However, this
is the ﬁrst report of a RASGRP3 mutation within a haematological
malignancy. Further screening for RASGRP3 and NF1 mutations was
not carried out due to their rarity (1/8 and 1/20 cases, respectively).
A recurrent mutation (p.Q114fs) was identiﬁed by WES in the
ligand, FLT3LG (25%, 2/8). Although FLT3LG mutations are rare in
haematological malignancies and have not been previously
reported in ALL, mutation of its receptor, FLT3, occurs in 10–15% of
ALL.3 Both FLT3LG mutant samples harboured mutations in other
RAS pathway genes (patient 3, KRAS, NRAS (n= 2), PTPN11; patient 9,
NRAS (n= 4)), suggesting that, similar to other components of the
RAS pathway, FLT3LG mutations coexist with other RAS gene
mutations in iAMP21-ALL. Similarly, samples with these mutations
may be responsive to inhibitors of the RAS pathway. The incidence
and biological effect of FLT3LG mutations therefore requires further
investigation in iAMP21-ALL. Moreover, the diversity of RAS pathway
gene mutations observed in this study raises the question
of optimum methods for mutation screening within a clinical
setting. A wide genomic capture method, along with conﬁrmation
of activation of the pathway through pERK expression, may be the
best future screening approach.
Although RAS gene mutations frequently co-occur in ALL, we
showed here that FLT3 mutations often occurred independently of
other mutations (78% cases) in iAMP21-ALL. Furthermore, we
identiﬁed a signiﬁcantly higher incidence of FLT3-ITD compared
with high hyperdiploid and B-other ALL, in which substitutions and
indels were common. The mutated FLT3 receptor constitutively
activates a number of downstream signalling pathways implicated
in leukaemogenesis (RAS/RAF/ERK, PI3K/AKT/mTOR and JAK/STAT5)
(Supplementary Figure 7).34,35 Despite the transcript expression
from the FLT3 mutant and normal alleles, pERK expression was
negative in a patient with FLT3-ITD at 4% VAF. This observation may
be a reﬂection of the lack of sensitivity of the assay or suggest
activation of an alternative pathway. Considering FLT3-ITD has been
associated with JAK/STAT pathway activation and is frequent in
Ph-like ALL, in which patients show a high incidence of tyrosine
kinase- and cytokine-signalling abnormalities, JAK/STAT pathway
activation and share a similar gene expression proﬁle to iAMP21-
ALL, the mutant FLT3 receptor may have a speciﬁc biological role in
iAMP21-ALL development.6,9,35 Therapeutic inhibitors are currently
being considered for the treatment of ALL patients with JAK/STAT
pathway deregulation or FLT3-ITD acute myeloid leukaemia (AML),
although the mutation must be present in the major clone or
overexpressed (in relation to the wild-type allele) in order to target
the majority of the leukaemic cells. Although FLT3-ITD had an
average VAF of 9% in iAMP21-ALL, this was not reﬂected in
the transcript expression ratio of wild-type to mutant allele in
iAMP21-ALL patients. The leukaemogenic potency and biological
function of subclonal FLT3-ITD alleles that are overexpressed
requires further investigation in order to explore the role of this
abnormality in iAMP21-ALL and assess the utility of such novel
targeted therapies in the treatment of this disease.
The same RAS mutation was retained in both the diagnostic and
xenograft cells of two patient samples with signiﬁcant mutation
burden (NF1 p.P1667S, VAF = 44%, patient 1 xenograft and NRAS
p.Q61H, VAF = 47%, patient 14 xenograft). The xenograft cells
showed sensitivity to the MEK1/2 inhibitor, selumetinib, in vitro.
A cell line model is not available for iAMP21-ALL and, due to the
rarity of this disease, only limited iAMP21-ALL xenograft material
was available. We have previously shown that in vitro sensitivity
of RAS pathway mutated ALL cells to selumetinib is mirrored
in NSG mice engrafted with primary ALL cells, with both showing
a dramatic reduction in viable cell numbers.8 Similarly, the
xenograft cells of two iAMP21-ALL patients who did not harbour
RAS pathway mutations were not sensitive to selumetinib and
showed a comparable response to non-mutated samples from our
previous study.8 Thus, the overall conclusion is that samples
with signiﬁcant RAS pathway mutation burden respond well to
selumetinib. Although the clinical beneﬁt of MEK inhibitors alone
or in combination with other chemotherapeutic agents/targeted
therapies is not well understood, clinical trials are ongoing in
speciﬁc forms of RAS/RAF/ERK mutant cancer, including childhood
ALL, to explore the most effective form of treatment and reduce
the potential for treatment resistance, a problem that emerged
in early studies of BRAF mutant malignant melanoma.26,36 In our
study, it was also apparent that (1) VAF of the mutation,
(2) potency of the mutated gene in activating the RAS/RAF/ERK
pathway, (3) type of mutation or biological function of the
gene and (4) additional genomic abnormalities may inﬂuence the
therapeutic response (Supplementary Figure 7). Certain genes and
protein-coding mutations vary in their level of activation of the
RAS/RAF/ERK pathway,37–39 as demonstrated by the variable pERK
expression between RAS pathway mutated samples in this study.
Furthermore, the importance of understanding the genomic
landscape in a given sample was demonstrated by the response
of xenograft cells from hypodiploid ALL patients that harboured
NRAS and NF1 (VAF450%) mutations to PI3K/mTOR, but not MEK,
inhibitors, despite the detection of pERK and pS6 levels.4 Although
further comprehensive genomic and biological investigations are
required to fully characterise those patients who may beneﬁt
from RAS/RAF/ERK pathway inhibition, here we indicate that
there is emerging potential in response to MEK1/2 inhibition in
iAMP21-ALL. These patients are currently treated with highly toxic,
intensive therapy.12,14 Therefore, the addition of MEK inhibitors
into the treatment regimen of iAMP21-ALL patients with RAS
pathway mutations in the major clone may enable modiﬁcation
of chemotherapy intensity.
In conclusion, this is the ﬁrst study to explore the mutational
landscape of iAMP21-ALL. A high incidence of RAS pathway
mutations was observed against which targeted RAS/RAF/ERK
pathway inhibitors may offer an additional therapeutic strategy to
the current highly toxic chemotherapeutic agents given to these
high-risk patients.
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